Cadrenal Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own69.02% Shs Outstand11.63M Perf Week12.00%
Market Cap16.55M Forward P/E- EPS next Y- Insider Trans0.37% Shs Float3.55M Perf Month-24.32%
Income- PEG- EPS next Q- Inst Own- Short Float / Ratio1.01% / 0.12 Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Interest0.04M Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.20 - 6.75 Perf YTD-66.02%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-79.26% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low16.67% ATR0.20
Employees1 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)34.63 Volatility10.66% 11.05%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.00 Prev Close1.40
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume310.66K Price1.40
Recom- SMA20-6.39% SMA50-31.56% SMA200-31.56% Volume0 Change0.00%
Mar-30-23 09:00AM
Mar-09-23 09:00AM
Feb-08-23 09:00AM
Feb-06-23 09:00AM
Feb-01-23 09:00AM
02:11PM Loading…
Jan-24-23 02:11PM
Jan-23-23 11:39AM
Jan-20-23 09:31AM
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MURPHY JOHN RAYMONDDirectorMar 21Buy1.3910,00013,900594,792Mar 22 04:01 PM
MURPHY JOHN RAYMONDDirectorMar 16Buy1.6720,00033,398574,792Mar 16 05:27 PM